{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibtizuelw24bemhcbr6vxwmy5qox72zexn4wn4flf3upzthmzt5ee",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mizyforkxkx2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiadis4oferdjx5k4oy3b2odwdro6xncyhfkzrssbxzzbnvk2hma7u"
    },
    "mimeType": "image/jpeg",
    "size": 89666
  },
  "path": "/news/2026-04-aad-subcutaneous-amlitelimab-aids-atopic.html",
  "publishedAt": "2026-04-08T22:50:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis (AD), according to the results of three phase 3 studies presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.",
  "title": "AAD: Subcutaneous amlitelimab aids atopic dermatitis outcomes through week 24"
}